Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cytek Biosciences (CTKB) EBT (2020 - 2026)

Cytek Biosciences filings provide 6 years of EBT readings, the most recent being -$4.0 million for Q4 2025.

  • On a quarterly basis, EBT fell 139.05% to -$4.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$29.8 million, a 423.62% decrease, with the full-year FY2025 number at -$29.8 million, down 423.53% from a year prior.
  • EBT hit -$4.0 million in Q4 2025 for Cytek Biosciences, up from -$7.8 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $10.3 million in Q4 2024 to a low of -$11.3 million in Q1 2025.
  • Median EBT over the past 5 years was -$2.4 million (2022), compared with a mean of -$2.2 million.
  • Biggest five-year swings in EBT: surged 1601.56% in 2021 and later crashed 5048.41% in 2025.
  • Cytek Biosciences' EBT stood at $444000.0 in 2021, then soared by 826.58% to $4.1 million in 2022, then decreased by 0.07% to $4.1 million in 2023, then soared by 151.11% to $10.3 million in 2024, then crashed by 139.05% to -$4.0 million in 2025.
  • The last three reported values for EBT were -$4.0 million (Q4 2025), -$7.8 million (Q3 2025), and -$6.8 million (Q2 2025) per Business Quant data.